Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8758946 | 0.87 | MAPT (0.41) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL4889715 | 0.87 | MAPT (0.41) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL574986 | 0.74 | NPSR1 (0.38) | MAPTALDH1A1POLBADRB1LMNA | |
| SCHEMBL29286373 | 0.73 | SIRT6 (0.49) | MAPTALDH1A1SIRT6POLBADRB1 | |
| Iodide SCHEMBL29895341 | 0.72 | SIRT6 (0.47) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL2484098 | 0.72 | MAPT (0.55) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL6151230 | 0.72 | SIRT6 (0.81) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL15271381 | 0.72 | SIRT6 (0.81) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL3439980 | 0.70 | POLB (0.73) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL378458 | 0.69 | MAPT (0.96) | MAPTALDH1A1SIRT6POLBADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217022-B2 | Analogues of 1,3-bis(4-nitrophenyl)triazenes, their pharmaceutically acceptable salts and N-acyl derivatives for tumour treatment | RUDJER BOSKOVIC INSTITUTE (HR) | 2012-07-10 | — | — | US | disclosed |
| US-20110224412-A1 | Analogues Of 1,3-Bis(4-Nitrophenyl)Triazenes, Their Pharmaceutically Acceptable Salts And N-Acyl Derivatives For Tumour Treatment | RUDJER BOSKOVIC INSTITUTE (HR) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224412-A1 | Analogues Of 1,3-Bis(4-Nitrophenyl)Triazenes, Their Pharmaceutically Acceptable Salts And N-Acyl Derivatives For Tumour Treatment | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BAD | MAPT 3013/4885ALDH1A1 2073/4885SIRT6 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.